Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.45 |
| ▸ | CRHR1 | P34998 | 6/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | PARG | Q86W56 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752895 | 0.82 | SMN1; SMN2 (0.43) | NPC1GAAAPEX1 | |
| SCHEMBL5119460 | 0.80 | CNR2 (0.56) | CNR2CRHR1CRHR2NPC1GAA | |
| SCHEMBL3755469 | 0.79 | CNR2 (0.46) | CNR2CRHR1CRHR2NPC1GAA | |
| SCHEMBL738179 | 0.75 | MEN1 (0.50) | HTT | |
| SCHEMBL1853671 | 0.72 | ALDH1A1 (0.56) | — | |
| SCHEMBL2680469 | 0.71 | CYP1A2 (0.54) | CRHR1CRHR2NPC1GAAPARG | |
| SCHEMBL30745333 | 0.68 | CNR2 (0.56) | CNR2NPC1GAAAPEX1CNR1 | |
| SCHEMBL25720574 | 0.65 | CYP1A2 (0.48) | CRHR1CRHR2NPC1PARG | |
| SCHEMBL21463869 | 0.65 | TSHR (0.51) | CNR2CRHR1CRHR2NPC1GAA | |
| SCHEMBL21463866 | 0.65 | TSHR (0.51) | CNR2CRHR1CRHR2NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297028-A1 | MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20070203125-A1 | Medicament Combinations for the Treatment of Respiratory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203125-A1 | Medicament Combinations for the Treatment of Respiratory Diseases | CHRM1, CHRM2, MTNR1B | CNR2 183/4885CRHR1 109/4885CRHR2 136/4885 |
| US-20100297028-A1 | MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | CHRM1, CHRM2, MTNR1B | CNR2 183/4885CRHR1 109/4885CRHR2 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.